Compare CCM & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCM | ELUT |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 25.2M |
| IPO Year | 2009 | 2020 |
| Metric | CCM | ELUT |
|---|---|---|
| Price | $3.74 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 4.0K | ★ 239.5K |
| Earning Date | 09-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,056,841.00 | $21,746,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $3.60 | $0.58 |
| 52 Week High | $10.77 | $5.12 |
| Indicator | CCM | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 33.78 | 34.51 |
| Support Level | $3.71 | $0.60 |
| Resistance Level | $4.00 | $0.81 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 10.68 | 26.17 |
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.